MoneyAM MoneyAM
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Research   Share Price   Awards   Indices   Market Scan   Company Zone   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Stock Screener   Forward Diary   Forex Prices   Director Deals   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Videos   Comparison Tables   Spread Betting   Broker Notes   Shares Magazine 
You are NOT currently logged in

 
Filter Criteria  
Epic: Keywords: 
From: Time:  (hh:mm) RNS:  MonAM: 
To: Time:  (hh:mm)
Please Note - Streaming News is only available to subscribers to the Active Level and above
 


SMALL-CAP WINNERS & LOSERS: Dalata expects record-breaking revenue

ALN

The following stocks are the leading risers and fallers among London Main Market small-caps on Wednesday.

----------

SMALL-CAP - WINNERS

----------

Dalata Hotel Group PLC, up 10% at 299.00 pence, 12-month range 239.00p - 385.18p. The Irish hotel operator reports that the strong recovery in trade seen in the first half of the year has continued into the second half. As a result, annual revenue for 2022 is expected to exceed €500 million for the first time in the company’s history. Adjusted earnings before interest, tax, depreciation and amortisation is expected to be above €182 million. Notes that all its new hotels are performing ahead of expectations. Says it is ‘cautiously’ optimistic for 2023. ‘2022 has been a very successful year for Dalata where we demonstrated our ability to bounce back from the challenges of Covid-19. I am very pleased with how we managed the recovery in trade of our existing hotels, opened six new hotels and added our first hotel in continental Europe,’ says Chief Executive Dermot Crowley.

----------

Genflow Biosciences PLC, up 5.5% at 2.98 pence, 12-month range 1.72p - 13.50p. The London-based biotechnology firm files a new patent application with the US Patent & Trademark Office in relation to its treatment Sirtuin-6 for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, an advanced form of non-alcoholic fatty liver disease. Genflow holds the exclusive licence for this application through Genflow Biosciences SRL, its Belgian subsidiary.

----------

SMALL-CAP - LOSERS

----------

SThree PLC, down 3.1% at 385.00 pence, 12-month range 312.50p - 495.00p. Staffing firm reports a ‘record’ performance in the year ended November 30, with double-digit net fee growth of 19% against the year prior. However, notes a ‘softer’ trading environment towards the end of the year. Fees rise to £430.6 million from £355.7 million year-on-year. Contract fees represent 78% of the firm’s fees in the year, up from 75% the previous year. Notes ‘uncertain’ macro-economic conditions and says it will monitor these trends across its regions.

----------

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.